BioSpace News Archive

The French authorities validate the start of the therapeutic trial to evaluate the safety of the ExOlin® device for patients suffering from poorly controlled type 1 diabetes with severe glycaemic fluctuations and prone to severe hypoglycaemia.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company’s common stock for the second quarter of 2022.

PTC Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted priority review of a supplemental new drug application for Evrysdi® to expand the indication to include pre-symptomatic infants under 2 months old with spinal muscular atrophy.

QIAGEN N.V. announced it has completed a U.S. government contract to equip public health laboratories across the country with the QIAcuity digital PCR system to monitor the spread of the COVID-19 pandemic by testing wastewater for the presence of SARS-CoV-2 pathogens.

MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that it has dosed the first patient in a global Phase 2 clinical trial of MTL-CEBPA in combination with second line standard of care sorafenib ) in advanced hepatocellular carcinoma.

VectorY Therapeutics announces a collaboration with Wageningen University to develop novel baculovirus-based technologies for the production of safe and affordable AAV gene therapies.

Lifebit announces a long-term partnership where Lifebit’s technology, Lifebit CloudOS, will power a cloud-based Trusted Research Environment to serve as the scalable and secure data management and analysis platform for researchers at the National Institute for Health Research Cambridge Biomedical Research Centre.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced an exclusive supply and technology agreement with Corning Incorporated.

Ocuphire Pharma, Inc. today announced that it will host a virtual investor R&D Day on Monday, January 31, 2022 from 10:00am to 12:15pm ET.

Leyden Laboratories B.V., (the “Company” or “Leyden Labs”) today announced closing a $140M Series B financing, bringing its total capital raised to approximately $200M in 2021.